Strategic Partner / Provider of Tangible Takeaways / Forecaster / Mentor / Servant Leader
Festival of Biologics Highlights: Biosimilars' Sustainability Challenge The recent Festival of Biologics shed light on the critical theme of long-term sustainability in the biosimilars market. Despite opportunities to improve regulatory, supply chain, and manufacturing processes, it's clear that existing market barriers and legislative effects are threatening biosimilars' future viability. Key Discussions: Barry Chester from Pfizer illuminated the event with talks on sustainability challenges and stakeholder roles in the evolving biosimilars landscape. An insightful panel featuring Steve Leher (moderator), Omar Hafez (Avalere Health), Hetal Patel (Celltrion Healthcare), and Barry Chester discussed access barriers, Part B biosimilar market dynamics, and strategies to mitigate rapid ASP erosion—highlighting operational losses, supply chain disruptions, and market exits. Understanding ASP: ASP, crucial for Medicare Part B reimbursements (now at ASP + 8%), is influenced by US sales data minus Medicaid, VA, DoD, and 340B exclusions. The fluctuating ASP impacts decisions by entities like the American Oncology Network and Sutter Health on when to switch biosimilars to optimize budgets. Innovative Solutions Proposed: Potential remedies to ASP erosion include value-based pricing, volume-based contracts, enhanced patient assistance programs, and aligning incentives through government policy. Discussions also touched on possible ASP percentage increases to better support provider economics. Looking Ahead: What might these developments mean for future launches of treatments like pembrolizumab, nivolumab, and ipilimumab? Share your thoughts and schedule a discussion on potential impacts to your organization or the broader Part B biosimilar market. https://lnkd.in/g5hJQy4y Stay tuned for Part D insights on Monday and an upcoming RCG Intel white paper on the US biosimilar industry. #FestivalOfBiologics #Biosimilars #HealthcareInnovation #PharmaIndustry
